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ABSTRACT 
The oral delivery of drugs is considered by decision-makers in the pharmaceutical 
industry to be the most appealing route of administration. This belief has led to the 
identification of many very successful drugs, but also to the downfall of some 
promising therapeutics that failed to meet criteria required for sufficient oral 
bioavailability. Efforts to correct these deficiencies have led to a plethora of creative 
strategies to overcome the physical, chemical, and biological barriers that limit the 
efficient and consistent delivery of drugs that are not readily absorbed following oral 
administration. The goal of this perspective is to describe these barriers to oral drug 
delivery in relation to some of the work currently being undertaken by the community 
of European scientists.  This perspective is not intended to be inclusive and the author 
apologizes in advance to the many scientists working in Europe whose recent work was 
not included.  
 
BACKGROUND 
It is unclear why people prefer taking a drug by the oral route over just about every 
other method; commonly these drugs are administered in a small- to moderate-sized 
pill or capsule form. Thinking about it, swallowing an object without mastication is 
contrary to all our default mechanisms for items that enter our mouth. Most mammals, 
other than canines that wolf their food, will examine a pill or capsule in their mouth 
and then reject it as something foreign and unacceptable. Indeed, pilling a cat can 
lead to a rather stressful outcome for the pet and lacerations for the owner. The cat, 
however, is merely following its natural survival instinct of first examining any 
material that enters its mouth prior to mastication and swallowing. While the 
reason(s) behind man’s willingness to so readily swallow unknown materials remain 
obscure and quite debatable, it leaves the pharmaceutical industry with a huge 
challenge of finding new therapeutic entities that can be delivered by this preferred 
route of administration.  
Successful oral delivery requires the selection of a drug that selectively hits a 
pharmaceutical target as well as the identification of a formulation for that drug 
which provides the required pharmacokinetic (PK) profile to result in a desired 
pharmacodynamic (PD) outcome. I have heard it said by several individuals associated 
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with the pharmaceutical industry that all the “low hanging fruit” of drug discovery is 
gone. What I believe these individuals are really saying is that most of the therapeutic 
targets where compound could be readily found with the required properties of high 
bioavailability, PK profile and safety window following oral administration have been 
identified and drugged (a term used by pharmaceutical executives to describe a 
commercially successful program). While the technologies that were used to prepare 
these successful oral formulations should not be trivialized, it has become clear that 
these previous technologies are insufficient to meet the challenges of potential drugs 
that are not readily absorbed following oral administration. Some of the challenges 
that must be addressed include instability in the gastrointestinal (GI) tract, poor 
uptake leading to low bioavailability, poor PK characteristics, insufficient target 
access, and off-target effects.  
I cannot definitively say whether those individuals predicting limited future 
opportunities for identifying promising oral drug candidates are right or wrong. There 
are some facts, however, that support their pessimism. Cumulatively, the 
pharmaceutical industry has spent billions searching for compounds with same 
properties of successful oral drugs [1]. Multiple, extensive, high-throughput screens 
(HTS) performed by the major pharmaceutical companies have looked at natural 
products as well as herbal and even traditional medicines [2]. Further, some of these 
HTS efforts were performed in combination with genomic, proteomic, kinomic, and 
metabalomic data [3-5]. These efforts have yielded a few molecules for the 
pharmaceutical industry to develop; the factor Xa inhibitor rivaroxaban being one of 
these few success stories [6]. There certainly has not been a tidal wave of new oral 
blockbusters, however, that some analysts had predicted when these new HTS 
technologies first identified [7].  
With the continued desire for new (and old) therapeutic agents to be administered by 
the oral route and the likelihood that HTS efforts and elaborate search methods will 
not identify as many new lead compounds as hoped [8], pharmaceutical scientists have 
logically focused on ways to improve the bioavailability of therapeutic agents that 
would not be otherwise considered appropriate for oral drug delivery. Previous studies 
to optimize the delivery of currently approved drugs have identified a wide range of 
creative methods to stabilize labile compounds that can deliver these materials to a 
specific segment of the GI tract. Building upon that previous knowledge base, more 
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recent efforts have focused on stability approaches and on strategies to improve the 
uptake of drugs that would otherwise not be absorbed following oral administration. 
Approaches currently being taken by European research groups to address some of 
these issues are the focus of this perspective.  
 
DRUGS DELIVERED BY THE ORAL ROUTE CONFRONT MULTIPLE CHALLENGES 
The complex digestive mechanisms of the GI tract are designed to safely, selectively, 
and effectively absorb as many nutrients as possible from our diet. Materials 
administered orally experience a very harsh environment in the stomach that is 
strongly acidic (pH 2-3) and contains a variety of enzymes that include lipases and 
proteases which normally function to initiate foodstuff digestion and destroy unwanted 
pathogens and toxins. Partly digested material (chyme) is then passed to the first 
segment of the small intestine (duodenum) where pancreatic enzymes, bicarbonate 
buffer, and bile salts are released from the common bile duct in coordination with the 
presence of chyme. This bolus of partly digested material then proceeds along the 
jejunum and ileum segments of the small intestine. During this transit the pH of the GI 
tract lumen rises from the acidic level in the stomach, to 5-6 in the duodenum, to 
neutrality (~pH 7) in the mid-to-distal jejunum; along the way large protein fragments 
are cut into small peptides, then processed further by peptidases at the apical surface 
of intestinal epithelial cells prior to selected uptake as amino acids as well as di- and 
tri-peptides [9]. Simultaneously, lipids in the GI tract have been solubilized by bile 
salts, broken down into free fatty acids and di- and tri-glycerides, and absorbed. 
Complex carbohydrates are cut into mono- and di-saccharides that are selectively 
taken in through specific transporters; similarly, vitamins and co-factors are also 
absorbed via specific uptake mechanisms. Poly-nucleic acids are extensively digested 
and taken up as nucleosides. Thus, the digestive processes of the GI tract are 
coordinated to sequentially breakdown complex nutrients into their elemental building 
blocks and then selectively absorb these nutritional elements in an organized fashion.  
In consideration of the many aspects of GI-mediated catabolic processes a variety of 
methods, such as those described above, can limit direct exposure of labile molecules 
to the most damaging aspects of these digestive events. Since the stomach, 
duodenum, and early jejunum are particularly harsh environments, many efforts have 
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focused on by-passing these regions and deliver poorly-absorbed drugs to the late 
jejunum and ileum. In essence, the goal is to allow passage of labile drugs through the 
stomach in a protective structure and then release them later in the GI tract to allow 
their absorption. Many poorly-absorbed drugs are not only labile but also are not 
readily transported across the intestinal epithelia once they reach the latter jejunum 
and ileum. Thus, acceptable methods to improve their uptake must also be identified 
[10]. In this perspective, some of the recent efforts taken by European scientists in 
these two areas of research are discussed. Additionally, I have tried to highlight some 
of the exceptional European expertise related to principles of oral drug delivery design 
and evaluation. I apologize in advance for omissions in this non-exhaustive and 
personal selection of recently published work.  
 
PROTECTION FROM THE HIGHLY ACIDIC ENVIRONMENT OF THE STOMACH 
It is not surprising that many drug candidate molecules can be altered or destroyed in 
the harsh, acidic, and enzymatically rich environments of the stomach, duodenum, 
and early jejunum. If these actions do not completely destroy the drug, its partial 
destruction or modification can lead to unacceptably low or inconsistent delivery 
profiles. The likelihood of destructive outcomes is further enhanced when the drug 
entity is retained in the stomach for extended periods of time which can occur due to 
diet and individual variations. One obvious way to address this situation is to isolate 
the drug from these harsh GI tract digestive environments as much as possible. There 
are well-established methods of coating capsules and tablets with polymers that are 
stable at the low pH of the stomach but dissolve in the more neutral pH experienced 
in the lumen of the late jejunum or ileum. Clearly, understanding the physiological 
characteristics of stomach retention and transit would be benefited by studies that 
examine parameters of how and why materials are retained by or pass through the 
stomach [11].  
Eudragit® (poly(meth)acrylate) polymers are an example of an acid-stable material 
that has been used to coat tablets and capsules to protect a drug compound against 
the low pH and enzymatic burden of the stomach and proximal small intestine. Hot-
melt extrusion technology has been applied to Eudragit 4155F and polyvinylpyrrolidone 
for the preparation of amorphous solid dispersions of drug/polymer systems with good 
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drug stability under conditions experienced in the stomach and characteristics that 
would target drug release in the colon [12]. Tannic acid combined with poly(N-
isopropylacrylamide) and poly(2-isopropyl-2-oxazoline) has been examined to provide 
hydrogen-bonded coating films with the promise of biocompatibility and lower critical 
solution temperature while still being pH-responsive at physiological temperatures 
[13]. Additionally, a food-grade lyotropic liquid crystal system composed of 
monolinolein and linoleic acid has been described that responds to pH variations as a 
reversible switch which results in changes of both structure and physical properties; 
characteristics that could facilitate targeted delivery to the small intestine or colon 
[14].  
Rather than a single capsule or tablet dosage form being protected during passage 
through the stomach, one could envisage coating individual particles. Solid pH-
dependent drug-releasing nanoparticles, prepared using hydroxypropyl-β-cyclodextrin 
and/or Eudragit® L100, have been described [15]. Evaluation of cationic liposomes 
coated with the pH-responsive anionic polymer Eudragit S100 suggests these materials 
could be used for delivery to the distal regions of the small intestine or to the colon 
[16]. With respect to colon targeting, Eudragit®-based drug delivery systems, 
prepared via hot melt extrusion, appear to work quite well for this task [17]. Another 
recently-described effort to produce enteric-coated microparticles for oral 
administration employed a water-in-oil-in-water solvent evaporation technique and 
used the pH-sensitive polymer cellulose acetate phthalate or poly(methyl 
methacrylate-acrylic acid) copolymer with varying amounts of polyvinyl alcohol as an 
emulsion stabilizer [18]. 
Due to the heterogeneity within some solid oral dosage systems it is difficult to obtain 
a precise prediction of the actual pH within the matrix microenvironment. Several 
strategies have been investigated to provide a more cohesive picture of conditions 
within such as system: integration of data from a pH indicator dye, fluorescence 
imaging and electron paramagnetic resonance (EPR) imaging [19]. While understanding 
pH changes that might be occurring within the dosage system is important, it is 
equally important to tune pH-regulated polymer coating systems for drug release with 
pH events occurring in the GI tract. Laboratory animals are the mainstay of preclinical 
testing for such oral drug delivery strategies with guinea pigs, rabbits, and pigs being 
commonly used species; each species has similarities and unique differences to man. A 
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recent evaluation of pH in the stomach, small intestine, and colon as well as water 
content in the same areas of these species has better defined some of these 
similarities and differences [20]. And finally, once a protective polymeric coating 
begins to dissolve, the material inside a coated capsule or tablet must leave the 
system quickly or it will be digested without ever reaching the epithelial surface for 
transmucosal uptake. Ordered mesoporous silica materials have been described as a 
promising material to produce immediate-release oral-dosage formulations [21].  
 
IMPROVING DRUG STABILITY IN THE GI TRACT  
Safe passage of labile therapeutic agents through the low pH environment of the 
stomach and duodenum does not ensure their stability against the exhaustive 
enzymatic burden of the small intestine. Polymeric structures offer one approach to 
shield labile materials until they can reach the mucosal surface (discussed below). A 
protective matrix, however, does not have to be in the nanoscale. For example, a 
biocompatible polymer such as ethylcellulose can be used to microencapsulate 
formulations to produce a liquid, sustained-release pharmaceutical for oral 
administration [22]. Similarly, a hydrogel system composed of methacrylic acid and 
poly(ethylene glycol) that releases entrapped drug with zero-order kinetics can be 
used [23]. Microparticles can also be produced by a spray congealing technology using 
Gelucire® 50/13 that would function as a hydrophilic carrier; data showed a 
significant improvement in the oral bioavailability of flavolignans found in Silybum 
Marianum dry extract [24].  
Alginate/chitosan microparticles containing a biopharmaceutical have been prepared 
by spray-drying an aqueous drug/alginate solution and subsequent cross-linking with 
Ca2+ and chitosan. These particles protect the incorporated biopharmaceutical until 
they are taken up by both M cells in Peyer's patches and into enterocytes; only M cell 
endocytosis appears to provide microparticle transport from the epithelium toward 
deeper sub-epithelial regions [25]. Promising gel-based emulsions for the preparation 
of self-microemulsifying drug delivery system (SMEDDS) were identified using 
molecular modeling and empirical force field calculations; the Flory-Huggins theory 
was used to study paired interactions of cyclosporine A with various types of 
surfactants to select a most promising candidate formulation for the oral delivery of 
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cyclosporine A [26]. Similarly, a system composed of poly(acrylic acid)-cysteine and 
reduced glutathione has been examined in vitro and in vivo as an oral drug delivery 
system and shown to improve the bioavailability of compounds that are P-gp and 
CYP450 substrates [27].  
All formulation excipients must be vetted by a variety of criteria to assess purity, 
stability, extent of systemic exposure, bio-distribution, elimination, etc. Excipients for 
oral drug formulations are typically selected from list of agents that have a long 
history of oral exposure, such as through food substances, and categorized as generally 
regarded as safe or GRAS. Some new stabilizing agents that are being examined as 
excipients to protect labile drugs fall into this GRAS list, others do not. Even GRAS 
molecules, however, might need further examination if they are delivered to a 
segment of the GI tract they normally would not reach. For example, gelatin would be 
considered as a GRAS material as it is found extensively in our diet where it is broken 
down in the upper GI tract. It is also the material used to make many capsules. Use of 
gelatin as an excipient in an oral delivery system that opens in the colon would place 
undigested gelatin in a segment of the GI tract inconsistent with its normal fate as a 
food substance or from a gelatin capsule. Here one might need to consider the 
potential actions of this GRAS excipient on the bacterial flora of the gut as well as its 
potential uptake into the systemic circulation at low levels. In this regard, a recent 
study has examined the uptake and distribution of a dextran derivative termed 
OTR4120 following oral administration and shown that this material is absorbed and 
metabolized with some accumulation in the spleen and kidney [28].   
Many new targets for specific cellular events are being validated by peptides that 
function to selectively disrupt protein/protein interfacial contacts. While peptides can 
be exquisitely specific and effective for in silico validation, their instability and poor 
bioavailability in the GI tract have limited their translation as drug candidates. Recent 
work to identify stable peptide forms as well as peptidomimetic approaches may allow 
for the oral delivery of peptide candidates that target selected protein-protein 
interactions implicated in disease pathogenesis [29]. Peptide modifications such as 
PEGylation, lipidisation, and multimerisation may help bring about these new peptide-
based therapeutic opportunities [30]. Another approach to protect peptides may come 
through an improved capacity to selectively inhibit specific intestinal peptidases. For 
example, studies examining high-resolution X-ray diffraction data of a 
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carboxypeptidase-Zn2+-citrate complex now provide an opportunity to design novel 
agents to regulate this enzyme [31].  
 
IMPROVING DRUG SOLUBILITY IN THE UPPER GI TRACT  
In other cases, poor solubility rather than poor stability is the cause of low oral 
bioavailability. The absorptive fate of lipophilic materials is dominated by entry into 
lacteals of the intestinal villi that drain into the lymphatic duct before entering into 
the systemic circulation. This route of entry avoids first-pass elimination events that 
can occur for drugs absorbed via the portal venous system that directly shunts to the 
liver and its extensive array of metabolic enzymes. Liposomes, a logical choice for the 
delivery of lipophilic drugs, were the first nanoparticles to be examined for oral drug 
delivery. Unfortunately, the instability of liposomes in the GI tract has been a serious 
problem for this application. 
Poorly soluble compounds identified in drug discovery are no longer immediately 
discarded and ways to solve the problems of delivery associated with these materials 
are being studied. Some of these efforts focus on identifying formulations that can 
enhance bioavailability and decrease variability typically that is frequently a concern 
of these materials. Lipid- and surfactant-based oral drug delivery systems can produce 
the desired formulations for the development of these compounds. A recent review of 
these approaches has provided a more cohesive picture of the physicochemical nature 
of suitable detergents and lipid excipients in relation to gastrointestinal digestion [32]. 
A thorough understanding of the physiological features of lymphatic-based uptake and 
metabolism is also critical in the design of successful lipid- or pro-drug-based drug 
delivery systems that could enhance lymphatic drug transport [33]. 
Cyclodextrins have been described as “an important tool in the formulator's 
armamentarium to improve drug solubility and dissolution rate for poorly water-
soluble drug candidates” and efforts have been made to predict whether cyclodextrins 
will be of benefit in creating a dosage form for a particular drug candidate [34]. 
Multiparticulate systems composed of α-cyclodextrin and soybean oil have also been 
described for the oral delivery of lipophilic drugs [35]. Such a system might also be 
used to target lymphatic uptake. Some nanomaterials, such as mesoporous silicon 
particles, function to improve the solubility of an otherwise poorly soluble drug as a 
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means to improve its uptake following oral delivery [36]. In this case, the particle 
itself does not appear to transport across epithelial barriers, but instead increased the 
permeation of the loaded poorly soluble drug. 
Other methods have been described to improve the oral delivery of lipophilic 
materials. Addition of the tetraether lipid glycerylcaldityl tetraether to liposomes 
prepared from egg phosphatidylcholine and cholesterol can stabilize these structures 
against the actions of bile salts; making them more promising carriers for oral drug 
delivery [37]. Nanostructured lipid carriers produced using a high pressure 
homogenization method and which can be loaded up to ~30% with drug have been 
shown to improve the oral delivery of testosterone undecanoate [38]. Tween 80-
coated polylactide-co-glycolide (PLGA) nanoparticles have been shown to effectively 
deliver the hydrophobic drug estradiol after an oral administration in a manner that 
was comparable to the injection of this hormone [39].  
The ability of liposomes to facilitate hydrophilic macromolecule delivery across 
polarized epithelial barriers can be improved by the incorporation of enhancing agents 
such as cholylsarcosine, cetylpyridinium chloride, and stearylamine [40]. Nanoparticles 
formed by Ca2+ nucleation of alginate and dextran sulfate bound to poloxamer were 
stabilized by chitosan and subsequently coated with albumin. These negatively 
charged nanoparticles improved the delivery of an incorporate macromolecule 
following oral administration [41]. A novel pulsatile release system for oral drug 
delivery has also been described that employs an enteric subcoating that eliminates 
drug diffusion through the gelled polymer coating layer prior to its erosion; the system 
incorporates varying ratios of a drug in the compression-coating layers in addition to 
the tablet core [42]. Thus, combinations of these new methodologies may offer novel 
approaches to facilitate the oral delivery of poorly soluble drug candidates that 
previously might have been rejected from oral screening.  
 
USING NANOSTRUCTURES IN ORAL DOSAGE FORMS 
While still unproven in clinical settings, nanostructures have been proposed to improve 
oral drug delivery efforts in several ways. One way is to protect labile materials prior 
to their presentation to the intestinal epithelial surface where they can then be 
absorbed. Since some animal data suggests nanostructure can are absorbed from the 
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intestinal lumen, these materials may help in the oral delivery of poorly-absorbed 
drugs. Such studies have shown that incorporated drugs have greater oral 
bioavailability compared to a solution form of the same drug. Finally, nanostructures 
are anticipated to provide a greater drug distribution at the apical surface of the 
intestinal epithelium when compared to other solid dosage forms; potentially 
improving the uptake outcome and/or absorption profile of the drug.  
A variety of new approaches to produce nanomaterials for the delivery of labile 
molecules have recently been described. Mannan is a plant polysaccharide composed 
of the sugar mannose. Nanogels made using an amphiphilic form of mannan can 
spontaneously incorporate proteins and other agents, potentially providing a new 
nanostructure oral delivery system [43]. Amphiphilic polyelectrolyte nanocomplexes 
prepared from polyallylamine grafted with palmitoyl chains and subsequently modified 
with quaternary ammonium moieties was shown to improve the uptake of incorporated 
insulin across Caco-2 cell monolayers in vitro [44]. The mechanism(s) by which these 
systems facilitate oral insulin uptake appear to be particularly complex as both active 
transport and reversible opening of tight junctions appeared to be involved [44].  
Nanoparticles, by themselves, are not necessarily prone to efficient transcytosis after 
contacting the apical surface of intestinal epithelial cells. It is therefore not surprising 
that recent studies with nanoparticles have demonstrated inclusion of hydroxypropyl-
β-cyclodextrin, an agent capable of modifying epithelial barrier function, can improve 
drug permeation across colonic pig mucosa. Nanoparticles made by coacervation of 
chitosan and DNA complexes which have a net positive zeta potential can protect an 
intercalated plasmid against nuclease degradation and improve transfection of M cells 
[45]. Importantly, these nanomaterials provided transfection with efficiency similar to 
polyethyleneimine-DNA complexes but without the cytotoxicity associated with this 
polymer. Related to delivery for oral immunization, targeting ligands have been 
described that increase antigen-particle uptake to intestinal antigen-presenting cells, 
including dendritic cells [46]. Silk fibroin matrices are biocompatible, slowly 
biodegradable, and endowed with excellent mechanical properties; they have been 
suggested for applications in oral drug delivery. In this regard, a recent review has 
examined the potential of using silk fibroin matrices to aid in the delivery of micro- or 
nanoparticles as a carrier or coating [47].   
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Nanoparticles, even in the absence of enhancing agents, have been touted as having 
the capacity to move across epithelial surfaces following oral delivery; some have 
even been described that can subsequently target selective sites within the body 
following mucosal transport. Recent studies using gold nanoparticles have suggested 
that particle size and surface properties can control the nature and extent of tissue 
distribution following oral uptake [48]. Another issue of using nanoparticles involves 
incorporation of a drug material, which can be an issue since some nanoparticle 
preparation techniques can damage labile drugs. Elements of two different techniques 
were used to prepare nanoparticles under less harsh conditions: hydrophobic ion 
pairing followed by encapsulation of an inter-polymer complex involving polyacrylic 
acid and a detergent. These particles were shown to increased oral bioavailability of 
leuprolide [49]. There are still many uncertainties regarding the production, fate, and 
safety of nanoparticles used for oral drug delivery with successful clinical applications 
likely requiring matching this technology with the right drug for the right indication. A 
study examining nanoparticle-mediated oral delivery of cyclosporine may have hit on 
one promising combination [50].  
 
INCREASING MUCOSAL ADHERANCE OF ORAL DOSAGE FORMS 
Efforts to orally deliver labile, poorly-absorbed drugs should benefit from bringing 
protective drug carriers into close proximity with the intestinal mucosa such that 
released drug can reach the epithelial cell surface before being destroyed in the 
intestinal lumen. Carriers with mucoadhesive properties could function to achieve this 
outcome. While the focus of this perspective is on drug delivery in the small intestine 
and colon, important advances in bioadhesive strategies for buccal administration [51, 
52] may provide important principles that could be applied to adhesion of materials to 
mucosal surfaces of the small intestine and colon. In this regard, β-limit dextrin (a 
starch derivative) was found to have significant mucoadhesive properties; similar to 
carbopol but superior to chitosan strategies [53].  
Chitosan is an important polymer for oral drug delivery because of its properties, 
safety, and availability; chitosan nanocapsules have shown promising results as 
carriers for oral peptide delivery. A recent study has examined the impact of 
molecular weight and degree of acetylation on chitosan nanocapsule production and 
Perspective   Mrsny 
13 
 
characteristics [54]. Further, chitosan treated Ca2+-alginate microparticles were 
screened to identify those having characteristics that would be consistent with 
improved delivery of naproxen to lower parts of GI tract [55]. Nanoparticles prepared 
from thiolated chitosan have mucoadhesive properties that can facilitate the oral 
delivery of labile drugs [56]. Modifications to chitosan, such a conjugation with 
mercaptonicotinic acid, can produce nanoparticles having strong mucoadhesive 
properties that make them useful for as vehicles for oral delivery of peptide drugs 
[57]. 
Incorporation of cyclodextrins in poly(anhydride) nanoparticles provides desirable 
bioadhesive properties and sufficient lipophilic drug loading to promote the oral 
bioavailability of (Class IV of the BCS) drugs displaying poor aqueous solubility and 
specific permeability characteristics [58]. Cyclodextrin-poly(anhydride) nanoparticles 
having bioadhesive properties can improve oral delivery of the lipophilic drug 
atovaquone [59]. Another approach to improve the proximity of an orally delivered 
drug to the mucosal surface is to place the drug in a patch that can be prepared using 
traditional microfabrication techniques and delivered by an orally-administered system 
[60, 61]. Overall, a variety of mucoadhesive materials are being studied to identify 
methods to bring labile, poorly-absorbed drugs to the epithelial surface where they 
have a greater chance of being absorbed than if they were released in the intestinal 
lumen.  
 
IMPROVING THE BIOAVAILABILITY OF POORLY ABSORBED DRUGS 
It is critical that the intestine functions as a selective barrier for it to function 
effectively in the absorption of nutrients in a safe manner. Non-self proteins in our 
diet cannot simply flood into our bodies for later catabolism or we would have massive 
immune responses to these dietary components and could not repeatedly eat the same 
food. The delicate but formidable permeability barrier established by intestinal 
epithelial cells limits uptake until these dietary elements are reduced to structures 
that are too small to load into major histocompatibility complex proteins involved in 
antigen presentation. Thus, despite excellent methods to safely guide materials 
through the stomach and early segments of the small intestine and deliver them to the 
apical surface of epithelial cells in the jejunum or ileum, these biotherapeutics cannot 
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be effectively absorbed at these distal sites until they are digested locally. This 
problem has been well-recognized and a large number of methods have been tested to 
improve epithelial permeability either through transcellular or paracellular routes.  
Enhancing agents used to date fall into several chemical categories: detergents, fatty 
acids, novel amino acids, lipid complexes, etc. While substantial uptake of protein and 
peptide therapeutics can be observed in animal models, only a few approaches have 
been translated to human clinical studies. The enhancing agents shown to be most 
successful to date for this clinical translation have been selected from a list of agents 
that are generally regarded as safe (GRAS). Since many poorly-absorbed compounds 
could be damaged by high concentrations of some GRAS agents, it is important to use 
enhancing agents that do not compromise these labile materials. For example, 
microemulsions composed of the surfactant didoceyldimethylammonium bromide, the 
co-surfactant propylene glycol, and triacetin have been shown to enhance the oral 
bioavailability of incorporated insulin [62].  
Salmon calcitonin, approved for the treatment of osteoporosis, has been examined in 
clinical studies as an oral dosage form that incorporates the permeation enhancer N-
(5-chlorosalicyloyl)-8-aminocaprylic acid [63]. Analysis of Phase III clinical trials have 
suggested that a tablet configuration of these materials can safely delivery, albeit at 
low levels of bioavailability, bioactive peptide [64]. Ways to improve the low 
bioavailability have been examined. Nanoparticles containing salmon calcitonin can be 
prepared by complexation of the peptide with the cationic amphiphilic polyelectrolyte 
poly(allyl)amine grafted with palmitoyl and quaternary ammonium moieties. The 
resulting positively-charged particle complexes can reduce free and serum calcium 
over 240 min following intra-jejunal administration demonstrating the oral delivery of 
biologically-active calcitonin [65]. 
The permeation enhancer N-[8-(2-hydroxybenzoyl) amino] caprylate, distinct from the 
enhancer described above, can increase the oral bioavailability of biologically-active 
glucagon-like peptide 1 or peptide YY 3-36 in healthy adults [66]. Thus, use of an 
enhancing agent can improve the oral delivery of poorly-absorbed drugs if they are 
kept sufficiently stabile in the intestinal lumen prior to uptake. In some ways, the 
complete strategy for a successful oral drug delivery would involve a system to deliver 
a labile drug in the presence of materials that inhibit destructive enzymes along with 
an absorption enhancer to facilitate uptake. This approach has been described using a 
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two-pulse colonic release system for insulin delivered with the protease inhibitor 
camostat mesilate and the absorption enhancer sodium glycocholate [67].  
For most individuals, oral drug delivery connotes systemic bioavailability. There are, 
however, important pharmaceutical targets associated with various cells of the GI 
tract itself and methods have been described to stabilize, protect, and deliver labile 
drugs locally in the intestine. One such example as been described in a study using 
mesoporous silica nanoparticles as a drug delivery system for the targeted inhibition of 
notch signaling in intestinal stem cells [68]. Another approach has been described 
where covalent modification of a therapeutic protein with glycosylphosphatidylinositol 
to would allow its association with lipid structures, allowing it to transfer from these 
structures to the membranes of target cells. It is proposed that these materials could 
also enable the transport of therapeutic proteins across the intestinal barrier and into 
the circulation [69].  
 
OPTIMIZATION OF ORAL DRUG DELIVERY SYSTEMS FOR THE FUTURE 
This perspective has focused on how European scientists are addressing the challenges 
of stabilizing labile drugs and finding ways to improve the oral bioavailability of 
poorly-absorbed drugs. The clinical impact of such work, however, may be optimized 
by methods that provide a defined pattern of drug delivery. These patterns could 
involve pulsatile/delayed delivery systems designed to elicit programmable lag phases 
preceding a prompt and quantitative, repeated or prolonged drug release. Formulation 
strategies behind delayed-release and pulsitile dosage forms intended for the 
pharmacological treatment of chronopathologies have recently been discussed [70]. 
Personalized medicine has been discussed for several years now as the way to 
optimally treat patients. Bringing that concept to a realistic outcome has many 
challenges. One such issue is being addressed by research examining the feasibility of 
solid systems that can enable flexible dosing such as dispensers for multiparticulate 
drug formulations, a solid dosage pen, and drug-loaded oral films which can be cut in 
individual sections [71]. Additionally, a device has been developed that allows for dose 
adjustment by the selected cutting of a monolithical drug carrier into defined 
individual doses [72].  
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Understanding the nature and characteristics of drug release from an oral delivery 
system is essential to predict the use of that system in that application and to project 
its potential use for other applications. A mathematical modeling approach to describe 
drug release and in vivo absorption has been described [73]. Such a study falls in line 
with research performed to identify dissolution methods that can be applied to 
correlate in vivo outcomes with in vitro performance assessments of oral drug delivery 
systems [74] with hydrodynamic events experienced by an extended release 
formulation being one parameter for consideration [75]. Similarly, simulations which 
includes pressure force exerted by GI motility, shear stress force generated during 
phases of GI transport and intermittent contact with intestinal fluids due to occasional 
encounters with intestinal air pockets have been described [76].  
Efforts have also been made to improve our understanding of the fate of oral delivery 
systems following their administration. European scientists have been at the forefront 
of establishing non-invasive methodologies of scintigraphy, magnetic tracking 
techniques like magnetic marker monitoring, magnetic moment imaging, AC 
biosusceptometry, and magnetic resonance imaging for this assessment [77]. 
Identification of optimal regions of the intestine for the delivery of a specific drug 
formulation can be determined using a remote-controlled capsule device that provides 
targeted drug delivery and is monitored for its location in the GI tract by scintigraphy 
[78]. Drugs designed to treat ulcerative colitis would obviously benefit from a delivery 
format directed to the colon. A pharmacoscintigraphic study in healthy volunteers 
using the MMX Multi Matrix System(®) (MMX™) to deliver propionyl-l-carnitine (PLC), a 
naturally occurring analogue of l-carnitine, demonstrated the colon to be the main site 
of PLC release and absorption [79].  
An issue that is not often appreciated early enough in oral formulation design is the 
potential impact that specific excipients used might have on the complex intestinal 
flora present in the GI tract. Thus, studies using the Simulator of the Human Intestinal 
Microbial Ecosystem (SHIME) to examine the impact of different ethylene vinyl acetate 
grades on the GI ecosystem following oral administration can anticipate and 
potentially mitigate expensive formulation changes at later stages of development 
[80]. Additionally, both regulatory agencies and pharmaceutical companies have 
become more appreciative that pediatric dosage forms must be designed to match 
unique issues associated with this patient population. Such concerns must be equally 
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considered when it comes to the identification of pediatric oral drug delivery 
strategies [81].  
 
OUTLOOK 
While the studies described in this perspective were authored by established European 
scientists, I cannot verify that that all of this work was performed in European 
laboratories. Clearly, scientific efforts have become more and more collaborative and 
many of these established European scientists work within international networks. One 
point that can be definitively stated, however, is that European pharmaceutical 
scientists have had tremendous impact on the successful development of therapeutics 
currently being administered by the oral route. Their ability to find innovative, 
elegant, and practical solutions to overcome the challenges to deliver materials to the 
GI tract has been impressive. With the inability of HTS efforts to find large numbers of 
obvious candidates that would be defined by current industry standards as promising 
lead compounds, new types of challenges now confront European pharmaceutical 
scientists. Unlike some other areas of the world, the European pharmaceutical 
community has enjoyed a fruitful collaborative arrangement between industrial and 
academic colleagues. I feel that continuation of this mutually-beneficial relationship 
will be critical to meet current challenges now faced by pharmaceutical companies to 
bring labile and/or poorly absorbed drug candidates through successful clinical 
development. With the ever-shrinking research budgets available to both academic 
and industrial scientists, success in the future for these programs may require not just 
creativity in the lab, but also new mechanisms and strategies to fund these essential 
studies. Some of these creative new mechanisms to bring academic and industrial 
groups together in multi-disciplinary, multi-regional efforts have included the FP-7 and 
IMI funding schemes. It is hoped that these approaches will prove fruitful and provide 
funding templates that can be expanded in the future.  
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